Early PrEgnancy Complications Testing

The aim of this study is the early (presymptomatic) detection of pregnancy complications, which could contribute to a preventive treatment.

Prenatal screening for an early detection of fetal abnormalities and pregnancy related complications is of great importance for both the fetus and the mother. The current follow-up consists of a physical screening (maternal blood pressure, edemas, weight, fundus altitude...), lab screenings (urine culture for screening asymptomatic bladder infection, urine stick for preeclampsia, sugar test for gestational diabetes, measuring cervix length for premature birth, Group B streptococcus screening), ultrasound monitoring (structural inspection, biometrics, placental function ...) and fetal monitoring with cardiotocography.

The recent introduction of the Non-Invasive Prenatal Testing (NIPT) caused a major change in prenatal diagnosis. NIPT allows the early (12 weeks gestational age) detection of chromosomal abnormalities, such as trisomy 21, with a very high sensitivity and specificity.

Trisomy 21 is with its incidence of 1/1000 live births only the tip of the iceberg of many other fetal abnormalities and gestational complications that can occur. Pregnancy complications, such as pre-eclampsia, intra-uterine growth retardation (IUGR) and preterm birth have a much higher incidence (up to 5-8% of all pregnancies) and are an important cause of maternal and neonatal morbidity and mortality.

The aim of this study is the early (presymptomatic) detection of pregnancy complications, which could contribute to a preventive treatment. Studies have shown that the major cause of these complications originate from defects in spiral artery remodeling and trophoblast invasion or an abnormal functioning placenta, during the 1st or 2nd trimester. Insufficient oxygen and nutrient flow to the placenta, caused by abnormal (narrowed diameter) spiral arteria, is the most proven underlying origin. These obstructing conditions can lead to a placenta in stress (hypoxia), and therefore potentially a fetus in stress (IUGR). General known is that these pathologies will lead to a different gene expression, which can be investigated by direct analysis of placental RNA (transcriptome) and DNA (methylation profiling). During the last decade, several high impact researchers (for example the research groups of Dennis Lo and Stephen Quake, founders of the current worldwide NIPT screening) have investigated gene expression profiles in the placenta in normal and complicated pregnancies, by analyzing the placental cell free DNA and RNA present in maternal plasma. Very recent findings indicate a huge potential in non-invasively profiling the placental transcriptome and methylome. Advances in next-generation sequencing and molecular analysis made it possible to measure circulating nucleic acids to improve the investigator's understanding of placental pathology and develop novel non-invasive biomarkers for pregnancy complications and monitoring high-risk pregnancies.

Eligibility Criteria:
Inclusion Criteria:

* Every pregnant woman, speaking and understanding Dutch, French or English

Exclusion Criteria:

* not able to understand and adhere to the informed consent and study procedures